OncoBEAMTM

Revolutionary liquid biopsy technology

OncoBEAM

Our OncoBEAM™ technology set the gold standard for ctDNA-based liquid biopsy testing as the first liquid biopsy technology used for oncology studies. It’s the most sensitive digital PCR approach available today. Proven to detect important mutations from 0.02% to 0.04% allele frequency, OncoBEAM technology ensures reliable molecular information for real-time monitoring of tumor response and subsequent therapy interventions.

Based on BEAMing (Bead, Emulsion, Amplification, and Magnetics), OncoBEAM combines emulsion digital PCR with magnetic beads and flow cytometry for highly sensitive detection and quantification of mutant tumor DNA molecules.

  1. 2003:

    OncoBEAM is first described in a study.1

  2. 2008:

    The field of liquid biopsy was birthed when investigators at Johns Hopkins School of Medicine successfully demonstrated the clinical utility of OncoBEAM in a landmark study of metastatic colorectal cancer patients.2

  3. 2009-2020:

    Nearly 100 peer-reviewed publications, more than 200 posters and publications, and at least 30 drugs have been developed using OncoBEAM technology.

Citations

1. Dressman D, Yan H, Traverso G, Kinzler KW, Vogelstein B. Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations. Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8817-22. doi: 10.1073/pnas.1133470100. Epub 2003 Jul 11. PMID: 12857956; PMCID: PMC166396.

2. Diehl F, Schmidt K, Durkee KH, Moore KJ, Goodman SN, Shuber AP, Kinzler KW, Vogelstein B. Analysis of mutations in DNA isolated from plasma and stool of colorectal cancer patients. Gastroenterology. 2008 Aug;135(2):489-98. doi: 10.1053/j.gastro.2008.05.039. Epub 2008 May 15. PMID: 18602395; PMCID: PMC2820386.

Tumor-specific tests

Tumor Specific Tests

AML

Genes Exons Codon(s) Mutations (Nucleotide Change)
IDH1 4 132 R132S [394C>A], R132G [394C>G], R132C [394C>T], R132H [395G>A], R132L [395G>T]
IDH2 4a 140 R140W [418C>T], R140Q [419G>A], R140L [419G>T]
4b 172 R172K [515G>A], R172M [515G>T]

Breast

Genes Exons Codon(s) Mutations (Nucleotide Change)
AKT1 2 17 E17K [49G>A]
ESR1 5 380 E380Q [1138G>C]
7 463 S463P [1387T>C]
8 534, 535, 536, 537, 538 V534E [1601T>A], P535H [1604C>A], L536H [1607T>A], L536P [1607T>C], L536R [1607T>G], L536Q [1607_1608delinsAG], Y537N [1609T>A], Y537S [1610A>C], Y537C [1610A>G], D538G [1613A>G]
PIK3CA 7 420 C420R [1258T>C]
9 542, 545, 546 E542K [1624G>A], E545G [1634A>G], E545K [1633G>A], Q546K [1636C>A]
20 1043, 1047 M1043I [3129G>T], H1047R [3140A>G], H1047L [3140A>T], H1047Y [3139C>T]

Colorectal

Additional mutations are available in PIK3CA(10,20)/AKT1(2)/ BRAF(15). For detailed information contact your local key Account Manager or drop us a line via info@sysmex-inostics.com

Genes Exons Codon(s) Mutations (Nucleotide Change)
KRAS 2 12,13 G12S [34G>A], G12R [34G>C], G12C [34G>T], G12D [35G>A], G12A [35G>C], G12V [35G>T], G13D [38G>A]
3 59, 61 A59T [175G>A], Q61H [183A>C, 183A>T], Q61L [182A>T]
4 117, 146 K117N [351A>C, 351A>T], A146T [436G>A], A146V [437C>T]
NRAS 2 12,13 G12S [34G>A], G12R [34G>C], G12C [34G>T], G12D [35G>A], G12A [35G>C], G12V [35G>T], G13R [37G>C], G13D [38G>A], G13V [38G>T]
3 59, 61 A59T [175G>A], Q61H [183A>C, 183A>T], Q61R [182A>G], Q61L [182A>T], Q61K [181C>A]
4 117, 146 K117N [351C>A, 351A>T], A146T [436G>A]
BRAF 15 600 V600E [1799T>A]
PIK3CA 10 542, 545, 546 E542K [1624G>A],E545G [1633G>A], E545K [1634A>G], Q546K [1636C>A]
20 1043, 1047 M1043I [3129G>T], H1047R [3140A>G], H1047L[3140A>T], H1047Y[3139C>T]
AKT1 2 17 E17K [49G>A]
BRAF 15 600 V600K [1798_1799delinsAA]

Giloma

Genes Exons Codon(s) Mutations (Nucleotide Change)
IDH1 4 132 R132S [394C>A], R132G [394C>G], R132C [394C>T], R132H [395G>A], R132L [395G>T]
IDH2 4a 140 R140W [418C>T], R140Q [419G>A], R140L [419G>T]
4b 172 R172K [515G>A], R172M [515G>T]

Lung

Genes Exons Codon(s) Mutations (Nucleotide Change)
BRAF 15 600 V600E [1799T>A]
EGFR 19 746, 747 E746_A750del [2235_2249del, 2236_2250del], E746_S752>V [2237_2255delinsT], L747_A750>P [2239_2248delinsC], L747_T751del [2240_2254del], L747_P753>S [2240_2257del]
20 790, 797 T790M [2369C>T], C797S [2389T>A, 2390G>C]
21 858, 861 L858R [2573T>G], L861Q [2582T>A]
KRAS 2 12, 13 G12S [34G>A], G12R [34G>C], G12C [34G>T], G12D[35G>A], G12A [35G>C], G12V [35G>T], G13D [38G>A]
3 61 Q61L [182A>T], Q61H [183A>T, 183A>C]

Melanoma

Genes Exons Codon(s) Mutations (Nucleotide Change)
BRAF 15 600 V600E [1799T>A], V600K [1798_1799delinsAA]
NRAS 3 61 Q61H [183A>C, 183A>T], Q61R [182A>G], Q61L [182A>T], Q61K [181C>A]

Pancreatic

Genes Exons Codon(s) Mutations (Nucleotide Change)
KRAS 2 12,13 G12S [34G>A], G12R [34G>C], G12C [34G>T], G12D [35G>A], G12A [35G>C], G12V [35G>T], G13D [38G>A]
3 59, 61 A59T [175G>A], Q61H [183A>C, 183A>T], Q61L [182A>T]
4 117, 146 K117N [351A>C, 351A>T], A146T [436G>A], A146V [437G>T]
NRAS 2 12,13 G12S [34G>A], G12R [34G>C], G12C [34G>T], G12D [35G>A], G12A [35G>C], G12V [35G>T], G13R [37G>C], G13D [38G>A], G13V [38G>T]
3 59, 61 A59T [175G>A], Q61H [183A>C, 183A>T], Q61R [182A>G], Q61L [182A>T], Q61K [181C>A]
4 117,146 K117N [351C>A, 351A>T], A146T [436G>A]

Prostate

Genes Exons Codon(s) Mutations (Nucleotide Change)
AR 4 702, 716 L702H [2105T>A], L702Q [2104_2106delinsACC, 2104_2106delinsACG, 2104_2106delinsACT, 2104_2106delinsACA], V716M [2148G>A]
5 742 W742L [2225G>T], W742C [2226G>T]
8 875, 877, 878, 896 H875Y [2623C>T], F877L [2629T>C, 2631C>A, 2631C>G], T878A [2632A>G], T878S [2633C>G], M896V [2686A>G], M896T [2687T>C]

The video below illustrates the main steps of the BEAMing process

  1. PCR amplification

  2. Formation of water-in-oil emulsions

  3. Breaking of the emulsions and hybridization to fluorescent probes

  4. Flow cytometry readout

Click to Play Video

For oncologists interested in learning more about the benefits of blood-based biopsies with OncoBEAM, visit www.Oncobeam.com